ERBB2 and breast carcinoma: DABIL‐4 also showed cytotoxic activity (IC50 ~ 2.3 nm) against NT2.5, a murine transgenic breast cancer cell line, which express rat Her2/neu [16] (Fig. S3A), supporting the potential versatility of this fusion protein toxin.